Disordered calcium metabolism during anticonvulsant treatment.
D000293:Adolescent; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001659:Biliary Tract / Q000378:metabolism; D001847:Bone Diseases / Q000139:chemically induced* / Q000188:drug therapy; D002118:Calcium / Q000378:metabolism*; D002648:Child; D002762:Cholecalciferol / Q000378:metabolism; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007408:Intestinal Absorption; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008659:Metabolic Diseases / Q000139:chemically induced; D010634:Phenobarbital / Q000009:adverse effects / Q000494:pharmacology; D010672:Phenytoin / Q000009:adverse effects / Q000494:pharmacology; D014316:Tritium; D014807:Vitamin D / Q000378:metabolism / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000139:chemically induced
D000927:Anticonvulsants; D014316:Tritium; D014807:Vitamin D; D002762:Cholecalciferol; D010672:Phenytoin; D002118:Calcium; D010634:Phenobarbital